John H Rossmeisl1, Jeryl C Jones, Kurt L Zimmerman, John L Robertson. 1. Department of Small Animal Clinical Sciences, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA. jrossmei@vt.edu
Abstract
OBJECTIVE: To analyze survival time and identify prognostic factors associated with outcome following discharge in dogs with primary brain tumors treated palliatively. DESIGN: Prospective case series. ANIMALS: 51 dogs with 5 histopathologic types of brain tumors. PROCEDURES: Owners with dogs examined from 2004 to 2008 were invited to participate if dogs had CT or MRI evidence of a brain mass that was histopathologically confirmed as a neoplasm upon death, dogs survived for ≥ 48 hours after hospital discharge, and treatments following discharge were limited to administration of prednisone or phenobarbital. Prognostic factors, including signalment, clinical signs (including duration), tumor type, tumor location, degree of peritumoral edema, lesion burden, and prescribed treatment, were evaluated. Survival time was estimated and animal- and tumor-specific variables evaluated as potential prognostic factors. RESULTS: The median survival time in all dogs was 69 days (95% confidence interval [CI], 18 to 201 days). Multivariate analyses identified neuroanatomic location as the only significant prognostic variable, with the survival time of dogs with infratentorial tumors (n = 18) being significantly shorter (median, 28 days; 95% CI, 19 to 68 days) than survival time of dogs with supratentorial (33) tumors (median, 178 days; 95% CI, 119 to 270 days). Seizures were the most common clinical sign associated with supratentorial tumors (24/33 [73%]) and central vestibular dysfunction with infratentorial tumors (12/18). CONCLUSIONS AND CLINICAL RELEVANCE: Dogs with palliatively treated primary brain tumors, particularly those with tumors in the cerebellum, pons, or medulla, had a poor prognosis. However, dogs with supratentorial tumors had survival times > 3 months.
OBJECTIVE: To analyze survival time and identify prognostic factors associated with outcome following discharge in dogs with primary brain tumors treated palliatively. DESIGN: Prospective case series. ANIMALS: 51 dogs with 5 histopathologic types of brain tumors. PROCEDURES: Owners with dogs examined from 2004 to 2008 were invited to participate if dogs had CT or MRI evidence of a brain mass that was histopathologically confirmed as a neoplasm upon death, dogs survived for ≥ 48 hours after hospital discharge, and treatments following discharge were limited to administration of prednisone or phenobarbital. Prognostic factors, including signalment, clinical signs (including duration), tumor type, tumor location, degree of peritumoral edema, lesion burden, and prescribed treatment, were evaluated. Survival time was estimated and animal- and tumor-specific variables evaluated as potential prognostic factors. RESULTS: The median survival time in all dogs was 69 days (95% confidence interval [CI], 18 to 201 days). Multivariate analyses identified neuroanatomic location as the only significant prognostic variable, with the survival time of dogs with infratentorial tumors (n = 18) being significantly shorter (median, 28 days; 95% CI, 19 to 68 days) than survival time of dogs with supratentorial (33) tumors (median, 178 days; 95% CI, 119 to 270 days). Seizures were the most common clinical sign associated with supratentorial tumors (24/33 [73%]) and central vestibular dysfunction with infratentorial tumors (12/18). CONCLUSIONS AND CLINICAL RELEVANCE: Dogs with palliatively treated primary brain tumors, particularly those with tumors in the cerebellum, pons, or medulla, had a poor prognosis. However, dogs with supratentorial tumors had survival times > 3 months.
Authors: Amy K LeBlanc; Christina Mazcko; Diane E Brown; Jennifer W Koehler; Andrew D Miller; C Ryan Miller; R Timothy Bentley; Rebecca A Packer; Matthew Breen; C Elizabeth Boudreau; Jonathan M Levine; R Mark Simpson; Charles Halsey; William Kisseberth; John H Rossmeisl; Peter J Dickinson; Timothy M Fan; Kara Corps; Kenneth Aldape; Vinay Puduvalli; G Elizabeth Pluhar; Mark R Gilbert Journal: Neuro Oncol Date: 2016-05-14 Impact factor: 12.300
Authors: Orr Rozov; Pablo E Piñeyro; Kurt L Zimmerman; Ian P Herring; Rachel Matusow; John H Rossmeisl; Bernard S Jortner; Jennifer Dreyfus Journal: Clin Case Rep Date: 2016-07-27
Authors: Emily J Tonogai; Shan Huang; Rachel C Botham; Matthew R Berry; Stephen K Joslyn; Gregory B Daniel; Zixin Chen; Jianghong Rao; Xiang Zhang; Falguni Basuli; John H Rossmeisl; Gregory J Riggins; Amy K LeBlanc; Timothy M Fan; Paul J Hergenrother Journal: Neuro Oncol Date: 2021-10-01 Impact factor: 13.029